GT-008 / Pentixapharm - LARVOL DELTA

Improving druggability of a promising tumor target by the novel glycosylation-dependent mAb GT-008 for treatment of solid tumors (AACR 2025) - "With its improved therapeutic window due to the strong differentiation between healthy and tumor tissue, GT-008 is exceptionally suitable for different therapeutic modalities, such as drug delivery (ADC, RIT) or cellular therapies (CARs). An in vitro and in vivo proof-of-concept study as therapeutic radioimmunoconjugate has been initiated."

IO biomarker • Oncology • Solid Tumor • CD24